Companies /Healthcare
Nurix Therapeutics Inc
NASDAQ: NRIX Biotechnology
$27.12
▼ $0.14 (−0.51%) today
Markets closed · 11:53pm ET

Nurix Therapeutics (NRIX) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
33%
EPS beat rate
−0.66%
Avg. EPS surprise
Consecutive EPS misses
NRIX vs Market · 30-day return after each reportNRIXS&P 500
−20%0%+20%−23.8%+1.6%Q2 25+31.8%+4.6%Q3 25−10.1%−2.0%Q4 25+5.9%+9.1%Q1 26+4.8%+2.8%Q2 26
−20%0%+20%Q2 25Q3 25Q4 25Q1 26Q2 26
NRIX EPS Trend · estimate vs actualEstimateActual
$0$2$4$-0.74$-0.52Q2 25$-0.85$-1.03Q3 25$-0.92$-0.82Q4 25$-0.76$-0.79Q1 26$-0.72$-0.81Q2 26$5.11$4.73Q3 26
$0$2$4Q2 25Q4 25Q2 26
NRIX Revenue Trend · estimate vs actualEstimateActual
$0$200.0M$400.0M$600.0M$17.5M$44.1MQ2 25$16.1M$7.9MQ3 25$13.4M$13.6MQ4 25$14.2M$6.3MQ1 26$15.3M$9.0MQ2 26$479.5M$673.1MQ3 26
$0$200.0M$400.0M$600.0MQ2 25Q4 25Q2 26

How Often Does Nurix Therapeutics Beat Earnings Estimates?

Nurix Therapeutics beat EPS estimates in 2 of its last 6 reported quarters, and has missed 3 quarters in a row.

NRIX quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q3 2026 Includes $653.2 million of one-time license revenue recognized from the Roche collaboration and $34.4 million in one-time G&A expenses for Roche transaction consulting and business development costs $4.73 est. $5.11 −7.50% $673.1M est. $479.5M +40.36%
Q2 2026 $-0.81 est. $-0.72 −13.07% $9.0M est. $15.3M −40.85%
Q1 2026 $-0.79 est. $-0.76 −3.32% $6.3M est. $14.2M −56.09%
Q4 2025 $-0.82 est. $-0.92 +10.85% $13.6M est. $13.4M +1.22%
Q3 2025 $-1.03 est. $-0.85 −21.08% $7.9M est. $16.1M −50.85%
Q2 2025 $-0.52 est. $-0.74 +30.15% $44.1M est. $17.5M +151.56%

Figures from SEC filings and company reports. Not investment advice.